BR112021002565A8 - Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto - Google Patents

Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto

Info

Publication number
BR112021002565A8
BR112021002565A8 BR112021002565A BR112021002565A BR112021002565A8 BR 112021002565 A8 BR112021002565 A8 BR 112021002565A8 BR 112021002565 A BR112021002565 A BR 112021002565A BR 112021002565 A BR112021002565 A BR 112021002565A BR 112021002565 A8 BR112021002565 A8 BR 112021002565A8
Authority
BR
Brazil
Prior art keywords
compound
tautomer
stereoisomer
synthesis
pharmaceutically acceptable
Prior art date
Application number
BR112021002565A
Other languages
English (en)
Other versions
BR112021002565A2 (pt
Inventor
De Francesco Raffaele
Donnici Lorena
Guidotti Luca
Iannacone Matteo
Di Fabio Romano
Summa Vincenzo
Prandi Adolfo
Randazzo Pietro
Gornati Davide
Grillo Alessandro
Ferrante Luca
Ivanova Bencheva Leda
DE MATTEO Marilenia
Ferrara Marco
Original Assignee
Irbm S P A
Promidis S R L
Istituto Naz Di Genetica Molecolare Ingm
Ospedale San Raffaele Srl
Antios Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irbm S P A, Promidis S R L, Istituto Naz Di Genetica Molecolare Ingm, Ospedale San Raffaele Srl, Antios Therapeutics Inc filed Critical Irbm S P A
Publication of BR112021002565A2 publication Critical patent/BR112021002565A2/pt
Publication of BR112021002565A8 publication Critical patent/BR112021002565A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTO, SAL FARMACEUTICAMENTE ACEITÁVEL, TAUTÔMERO OU ESTEREOISÔMERO DO MESMO, COMPOSIÇÃO FARMACÊUTICA, PROCESSO PARA A SÍNTESE E USO DO DITO COMPOSTO A presente invenção refere-se a compostos que são inibidores do vírus da hepatite B (HBV). Os compostos da presente invenção são úteis sozinhos ou em combinação com outros agentes para tratamento, melhora, prevenção ou cura da infecção por HBV e condições relacionadas. A presente invenção também se refere a composições farmacêuticas contendo os ditos compostos.
BR112021002565A 2018-08-10 2019-08-09 Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto BR112021002565A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18188409.9A EP3608326A1 (en) 2018-08-10 2018-08-10 Tricyclic inhibitors of hepatitis b virus
EP18188409.9 2018-08-10
PCT/EP2019/071408 WO2020030781A1 (en) 2018-08-10 2019-08-09 Tricyclic inhibitors of hepatitis b virus

Publications (2)

Publication Number Publication Date
BR112021002565A2 BR112021002565A2 (pt) 2021-05-11
BR112021002565A8 true BR112021002565A8 (pt) 2022-10-18

Family

ID=63209240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021002565A BR112021002565A8 (pt) 2018-08-10 2019-08-09 Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto

Country Status (7)

Country Link
US (2) US11504382B2 (pt)
EP (2) EP3608326A1 (pt)
JP (1) JP7436454B2 (pt)
CN (1) CN113272309B (pt)
BR (1) BR112021002565A8 (pt)
CA (1) CA3110098A1 (pt)
WO (1) WO2020030781A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597637A1 (en) * 2018-07-19 2020-01-22 Irbm S.P.A. Inhibitors of hepatitis b virus
UY38705A (es) 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
WO2022206879A1 (zh) * 2021-03-31 2022-10-06 苏州晶云药物科技股份有限公司 氨磺酰基吡咯酰胺类化合物的晶型及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1587473A4 (en) * 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
US7361743B2 (en) 2004-02-11 2008-04-22 Pfizer Inc Lincomycin derivatives possessing antibacterial activity
EP2328890B1 (en) 2008-08-06 2012-01-25 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
US9073940B2 (en) * 2009-11-13 2015-07-07 Merck Serono Sa Tricyclic pyrazol amine derivatives
CN103889953B (zh) 2011-07-01 2016-06-08 巴鲁﹒S﹒布隆伯格研究所 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物
JP2014534206A (ja) * 2011-10-17 2014-12-18 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤
SG10201608528YA (en) 2011-12-21 2016-12-29 Novira Therapeutics Inc Hepatitis b antiviral agents
EP2938338A4 (en) 2012-12-27 2016-11-23 Univ Drexel NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9597332B2 (en) 2014-12-02 2017-03-21 Novira Therapeutics, Inc. Sulfide alkyl compounds for HBV treatment
AU2015358561A1 (en) 2014-12-02 2017-06-08 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for HBV treatment
US9765050B2 (en) 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
NZ739139A (en) 2015-08-05 2023-01-27 Indivior Uk Ltd Dopamine d3 receptor antagonists having a bicyclo moiety
WO2018053157A1 (en) * 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
AU2017353986B2 (en) * 2016-11-07 2021-08-19 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途

Also Published As

Publication number Publication date
CN113272309B (zh) 2024-02-23
CA3110098A1 (en) 2020-02-13
BR112021002565A2 (pt) 2021-05-11
WO2020030781A1 (en) 2020-02-13
US20230076319A1 (en) 2023-03-09
CN113272309A (zh) 2021-08-17
EP3608326A1 (en) 2020-02-12
JP2021534132A (ja) 2021-12-09
EP3833672A1 (en) 2021-06-16
US20220110943A1 (en) 2022-04-14
JP7436454B2 (ja) 2024-02-21
US11504382B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
BR112018075465A2 (pt) agentes antivirais de hepatite b
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112018067964A2 (pt) agentes antivirais para hepatite b
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
BR112021002565A8 (pt) Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
UY37998A (es) Agentes antivirales contra la hepatitis b
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BRPI0608245A2 (pt) compostos; processo para a sua fabricação; composições farmacêuticas; método para o tratamento e/ou prevenção de doenças que estejam associadas à modulação de receptores de sst subtipo 5 e uso dos compostos
BR112017019699A2 (pt) derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso
CL2008002995A1 (es) Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih.
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BR112014010401A2 (pt) inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ANTIOS THERAPEUTICS, INC. (US)

B25C Requirement related to requested transfer of rights

Owner name: ANTIOS THERAPEUTICS, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO 870230031080 DE 13/04/2023 E NECESSARIO GRU 248 PARA ALTERACAO DE SEDE DO DEPOSITANTE ?ANTIOS THERAPEUTICS, INC.? PELA DIVERGENCIA ENTRE O ATUAL ENDERECO E O CONSTANTE NO DOCUMENTO DE CESSAO.

B25G Requested change of headquarter approved

Owner name: ANTIOS THERAPEUTICS, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: OSPEDALE SAN RAFFAELE S.R.L. (IT) ; ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) ; IRBM S.P.A. (IT)